1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
2020 Alcohol Addiction Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

2020 Alcohol Addiction Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

  • February 2020
  • 133 pages
  • ID: 5863883
  • Format: PDF
  • VPAResearch

Summary

Table of Contents

The 2020 Alcohol Addiction pipeline report presents a comprehensive overview of the research and development of Alcohol Addiction drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Research phase, 19 drugs in pre-clinical phase, 3 drugs in phase 1, ten drugs in phase 2, one drug in pre-registration phase

As of February 2020, the Alcohol Addiction pipeline remains robust with 36 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Alcohol Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic uptake inhibitors; Aldehyde dehydrogenase 2 inhibitors; Alpha 1 adrenergic receptor antagonist; Alpha3 beta4 nAChR partial agonist; Alpha3 beta4 nicotinic receptor antagonists; Alpha4 Beta2 nAChR antagonist; CACNA2D1 protein modulators; CB1 and CB2 receptor agonist; Dopamine uptake inhibitors; GABA A receptor antagonist; GABA B receptor agonists; Ghrelin receptor inverse agonist; Glucocorticoid receptor II (GR) antagonists; Histamine H1 receptor antagonists; Histamine H3 receptor antagonist; Metabotropic glutamate receptor 5 (mGluR5) antagonists; NMDA receptor antagonist; Nociceptin opioid receptor (NOP) agonists; Opioid receptor antagonist; Orexin-1 receptor antagonist; PDE3 inhibitor; PDE4 inhibitor; PDE7 inhibitor; PKC_epsilon Inhibitors; Serotonin 2A receptor antagonists; Serotonin 3 receptor antagonists; Serotonin uptake inhibitors; Src-Family kinase inhibitors .

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Alcohol Addiction drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

Publisher Expertise
Our online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

Scope:
• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Alcohol Addiction development
• Alcohol Addiction pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Alcohol Addiction pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Alcohol Addiction pipeline candidates included
• Business overview and snapshot of all companies involved in Alcohol Addiction pipeline are included
• Latest market and pipeline developments are provided in the report

Alcohol Addiction pipeline companies included in the report are- Adial Pharmaceuticals Inc, Amygdala Neurosciences Inc, Aptinyx Inc, Arbor Pharmaceuticals LLC, Assuage Pharmaceuticals Inc, Astraea Therapeutics LLC, AstraZeneca Plc, BioCorRx Inc, Bioprojet SCR, Chronos Therapeutics Ltd, Confluence Pharmaceuticals LLC, Corcept Therapeutics Inc, Curemark LLC, Dicerna Pharmaceuticals Inc, Eli Lilly and Co, Kinnov Therapeutics SAS, Kinoxis Therapeutics Pty Ltd, Kyorin Pharmaceutical Co Ltd, Laboratorio Farmaceutico CT Srl, Lohocla Research Corp, Mapreg SAS, Mind Medicine Inc, Montisera Ltd, Omeros Corp, Osmotica Pharmaceutical Corp, Pfizer Inc, SK Biopharmaceuticals Co Ltd, Sosei Heptares, South Plains Biotechnology Inc, Syntropharma Ltd, Tonix Pharmaceuticals Holding Corp, VM Discovery Inc, Zynerba Pharmaceuticals Inc

Alcohol Addiction pipeline drugs profiled in the report include- AD-04 (ondansetron), ANS-6637, NYX-783, gabapentin enacarbil , AP-202, AT-1001, nociceptin opioid receptor for Alcohol Addiction, saracatinib difumarate (AZD0530), BICX101, BICX102, BPI.3656B, CTDP-002, acamprosate calcium , Glucocorticoid receptor antagonist for Alcohol Dependance, CM-1212, ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders, odelepran (LY-2196044), KT-110 (cyproheptadine and prazosin), KNX100, ibudilast, GET73, Nezavist, MAP4343, 18-MC (18-Methoxycoronaridine), D15, OMS527, OS-440 (arbaclofen extended release), PF-05190457, SKL10406, Orexin OX1 Antagonists for Addiction, Tetracycline Analogs for Alcohol Use Disorder, Nalsyn, TNX-102, VMD-2202, cannabidiol (ZYN002), naltrexone hydrochloride

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Inclusion Body Myositis (IBM) - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 70 pages

Inclusion Body Myositis (IBM) - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis - Pipeline Review, H1 2020, provides an overview ...


ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on